Skip to main content

Topical lineage-negative progenitor-cell therapy for diabetic wounds.

Publication ,  Journal Article
Lin, CD; Allori, AC; Macklin, JE; Sailon, AM; Tanaka, R; Levine, JP; Saadeh, PB; Warren, SM
Published in: Plast Reconstr Surg
November 2008

BACKGROUND: Impaired diabetic wound healing is due, in part, to defects in mesenchymal progenitor cell tracking. Theoretically, these defects may be overcome by administering purified progenitor cells directly to the diabetic wound. The authors hypothesize that these progenitor cells will differentiate into endothelial cells, increase wound vascularity, and improve wound healing. METHODS: Lineage-negative progenitor cells were isolated from wild-type murine bone marrow by magnetic cell sorting, suspended in a collagen matrix, and applied topically to full-thickness excisional dorsal cutaneous wounds in diabetic mice. Application of lineage-positive hematopoietic cells or acellular collagen matrix served as comparative controls (n = 16 for each group; n = 48 total). Time to closure and percentage closure were calculated by morphometry. Wounds were harvested at 7, 14, 21, and 28 days and then processed, sectioned, stained (lectin/DiI and CD31), and vascularity was quantified. RESULTS: : Wounds treated with lineage-negative cells demonstrated a significantly decreased time to closure (14 days) compared with lineage-positive (21 days, p = 0.013) and collagen controls (28 days, p = 0.004), and a significant improvement in percentage closure at 14 days compared with the lineage-positive group (p < 0.01) and the collagen control (p < 0.01). Fluorescently tagged lineage-negative cells remained viable in the wound for 28 days, whereas lineage-positive cells were not present after 7 days. Lineage-negative, but not lineage-positive, cells differentiated into endothelial cells. Vascular density and vessel cross-sectional area were significantly higher in lineage-negative wounds. CONCLUSION: Topical progenitor-cell therapy successfully accelerates diabetic wound closure and improves wound vascularity.

Duke Scholars

Published In

Plast Reconstr Surg

DOI

EISSN

1529-4242

Publication Date

November 2008

Volume

122

Issue

5

Start / End Page

1341 / 1351

Location

United States

Related Subject Headings

  • Wound Healing
  • Surgery
  • Skin Ulcer
  • Skin
  • Receptors, Leptin
  • Mice, Mutant Strains
  • Mice, Inbred C57BL
  • Mice
  • Injections, Intralesional
  • Immunomagnetic Separation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lin, C. D., Allori, A. C., Macklin, J. E., Sailon, A. M., Tanaka, R., Levine, J. P., … Warren, S. M. (2008). Topical lineage-negative progenitor-cell therapy for diabetic wounds. Plast Reconstr Surg, 122(5), 1341–1351. https://doi.org/10.1097/PRS.0b013e318188217b
Lin, Clarence D., Alexander C. Allori, Jared E. Macklin, Alexander M. Sailon, Rica Tanaka, Jamie P. Levine, Pierre B. Saadeh, and Stephen M. Warren. “Topical lineage-negative progenitor-cell therapy for diabetic wounds.Plast Reconstr Surg 122, no. 5 (November 2008): 1341–51. https://doi.org/10.1097/PRS.0b013e318188217b.
Lin CD, Allori AC, Macklin JE, Sailon AM, Tanaka R, Levine JP, et al. Topical lineage-negative progenitor-cell therapy for diabetic wounds. Plast Reconstr Surg. 2008 Nov;122(5):1341–51.
Lin, Clarence D., et al. “Topical lineage-negative progenitor-cell therapy for diabetic wounds.Plast Reconstr Surg, vol. 122, no. 5, Nov. 2008, pp. 1341–51. Pubmed, doi:10.1097/PRS.0b013e318188217b.
Lin CD, Allori AC, Macklin JE, Sailon AM, Tanaka R, Levine JP, Saadeh PB, Warren SM. Topical lineage-negative progenitor-cell therapy for diabetic wounds. Plast Reconstr Surg. 2008 Nov;122(5):1341–1351.

Published In

Plast Reconstr Surg

DOI

EISSN

1529-4242

Publication Date

November 2008

Volume

122

Issue

5

Start / End Page

1341 / 1351

Location

United States

Related Subject Headings

  • Wound Healing
  • Surgery
  • Skin Ulcer
  • Skin
  • Receptors, Leptin
  • Mice, Mutant Strains
  • Mice, Inbred C57BL
  • Mice
  • Injections, Intralesional
  • Immunomagnetic Separation